The Biotech Startups Podcast

Part 3 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

Part 2 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomic. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

Part 1 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Vizgen’s technology will aid the acceleration of biological research and discovery to advance human health

Part 3 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science.

Part 2 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by BD. He has also taught at MIT Sloan, authored 10 patents, and won the 2019 International Society for the Advancement of Cytometry Innovation Award.

Part 1 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by BD. He has also taught at MIT Sloan, authored 10 patents, and won the 2019 International Society for the Advancement of Cytometry Innovation Award.

Part 3 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Part 2 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Part 1 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Part 3 of 3. My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.

Part 2 of 3. My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.

My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.

Part 3 of 3. My guest for this week’s episode is Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments, a full lifecycle life sciences investment firm dedicated to solving the most challenging unmet patient needs. Stephanie is a seasoned expert and leader in business development, strategic partnerships, communications, and investor relations.

Part 2 of 3. My guest for this week’s episode is Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments, a full lifecycle life sciences investment firm dedicated to solving the most challenging unmet patient needs. Stephanie is a seasoned expert and leader in business development, strategic partnerships, communications, and investor relations.

Part 1 of 3. My guest for this week’s episode is Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments, a full lifecycle life sciences investment firm dedicated to solving the most challenging unmet patient needs. Stephanie is a seasoned expert and leader in business development, strategic partnerships, communications, and investor relations.

Part 3 of 3. My guest for this week’s episode is Kittu Kolluri, Founder and Managing Director of Neotribe Ventures, an early- and growth-stage venture capital firm investing in companies that solve hard technical problems and disrupt non-traditional industry sectors.

Part 2 of 3. My guest for this week’s episode is Kittu Kolluri, Founder and Managing Director of Neotribe Ventures, an early- and growth-stage venture capital firm investing in companies that solve hard technical problems and disrupt non-traditional industry sectors.

Part 1 of 3. My guest for this week’s episode is Kittu Kolluri, Founder and Managing Director of Neotribe Ventures, an early- and growth-stage venture capital firm investing in companies that solve hard technical problems and disrupt non-traditional industry sectors. Neotribe is led by a team of serial entrepreneurs with a track record of supporting and advising startups from seed round to IPO.

Part 3 of 3. My guest for this week’s episode is Fengru Lin, Founder and CEO of TurtleTree, a biotech company revolutionizing food for good. Having raised a 40 million dollar Series A, TurtleTree is creating cell-based milk, with a current focus on releasing LF+, the world’s first sustainably produced lactoferrin made with cutting-edge precision fermentation technology.

Part 2 of 3. My guest for this week’s episode is Fengru Lin, Founder and CEO of TurtleTree, a biotech company revolutionizing food for good. Having raised a 40 million dollar Series A, TurtleTree is creating cell-based milk, with a current focus on releasing LF+, the world’s first sustainably produced lactoferrin made with cutting-edge precision fermentation technology.

Part 1 of 3. My guest for this week’s episode is Fengru Lin, Founder and CEO of TurtleTree, a biotech company revolutionizing food for good. Having raised a 40 million dollar Series A, TurtleTree is creating cell-based milk, with a current focus on releasing LF+, the world’s first sustainably produced lactoferrin made with cutting-edge precision fermentation technology. Prior to TurtleTree, Fengru worked at UL, Salesforce, and Google, gaining a tremendous amount of experience in sales and business development.

Part 4 of 4. My guest for this week’s episode is Sandy Paige, co-managing director of the Seabright Ventures Fund, a search fund investing in the US middle market, with a focus on life sciences and cleantech.

Part 3 of 4. My guest for this week’s episode is Sandy Paige, co-managing director of the Seabright Ventures Fund, a search fund investing in the US middle market, with a focus on life sciences and cleantech. Sandy is an expert CEO, most recently leading and scaling Explora BioLabs before its acquisition by Charles River Laboratories for $295 Million.

Part 2 of 4. My guest for this week’s episode is Sandy Paige, co-managing director of the Seabright Ventures Fund, a search fund investing in the US middle market, with a focus on life sciences and cleantech. Sandy is an expert CEO, most recently leading and scaling Explora BioLabs before its acquisition by Charles River Laboratories for $295 Million.

Part 1 of 4. My guest for this week’s episode is Sandy Paige, co-managing director of the Seabright Ventures Fund, a search fund investing in the US middle market, with a focus on life sciences and cleantech. Sandy is an expert CEO, most recently leading and scaling Explora BioLabs before its acquisition by Charles River Laboratories for $295 Million dollars.

Part 3 of 3. My guest for this week’s episode is Maneesh Jain, CEO and Co-Founder of Mirvie, a life science company that predicts pregnancy complications before they happen by revealing the underlying biology of pregnancy health. Mirvie is dedicated to shaping the future of pregnancy health through simple, personalized blood tests. Before Mirvie, Maneesh was a founder, CEO, or executive of five successful start-ups, which include Parallele Bioscience, Auriphex Bioscience, Ion Torrent, Butterfly Network, and Cirina.

Part 2 of 3. My guest for this week’s episode is Maneesh Jain, CEO and Co-Founder of Mirvie, a life science company that predicts pregnancy complications before they happen by revealing the underlying biology of pregnancy health. Mirvie is dedicated to shaping the future of pregnancy health through simple, personalized blood tests.

Part 1 of 3. My guest for this week’s episode is Maneesh Jain, CEO and Co-Founder of Mirvie, a life science company that predicts pregnancy complications before they happen by revealing the underlying biology of pregnancy health. Mirvie is dedicated to shaping the future of pregnancy health through simple, personalized blood tests. Before Mirvie, Maneesh was a founder, CEO, or executive of five successful start-ups, which include Parallele Bioscience, Auriphex Bioscience, Ion Torrent, Butterfly Network, and Cirina.

Part 3 of 3. My guest for this week’s episode is Alok Tayi, Founder of Vibe Bio, a life science company that funds and guides high-potential drug programs through value inflection points. Vibe Bio’s core comprises a community of scientists, patients, and partners dedicated to helping biotechs find the promising treatments that patients deserve.

Part 2 of 3. My guest for this week’s episode is Alok Tayi, Founder of Vibe Bio, a life science company focused on funding & guiding high-potential drug programs through value inflection points. Vibe Bio’s core comprises a community of scientists, patients, and partners dedicated to helping biotechs find the promising treatments that patients deserve.

Part 1 of 3. My guest for this week’s episode is Alok Tayi, Founder of Vibe Bio, a life science company focused on funding & guiding high-potential drug programs through value inflection points. Vibe Bio’s core is a community of scientists, patients, and partners that are dedicated to helping biotechs find the promising treatments that patients deserve.

Part 3 of 3. My guest for this week’s episode is James Evans, Founder and CEO of PhenoVista Biosciences, a contract research organization that works with biopharma clients of all sizes, from start-ups to established global companies.

Part 2 of 3. My guest for this week’s episode is James Evans, Founder and CEO of PhenoVista Biosciences, a contract research organization that works with biopharma clients of all sizes, from start-ups to established global companies.

Part 1 of 3. My guest for this week’s episode is James Evans, Founder and CEO of PhenoVista Biosciences, a contract research organization that works with biopharma clients of all sizes, from start-ups to established global companies.

Part 3 of 3. My guest for this week’s episode is Steve Visco. Steve is the Co-founder, CTO, and CEO of PolyPlus. Before PolyPlus, Steve worked at Lawrence Berkeley National Lab as a Principal Investigator, running several programs in the field of solid state ionics, developing an extensive patent portfolio, much of which has been licensed to industry.

Part 2 of 3. My guest for this week’s episode is Steve Visco. Steve is the Co-founder, CTO, and CEO of PolyPlus. Before PolyPlus, Steve worked at Lawrence Berkeley National Lab as a Principal Investigator, running several programs in the field of solid state ionics, developing an extensive patent portfolio, much of which has been licensed to industry.

Part 1 of 3. My guest for this week’s episode is Steve Visco. Steve is the Co-founder, CTO, and CEO of PolyPlus. Before PolyPlus, Steve worked at Lawrence Berkeley National Lab as a Principal Investigator, running several programs in the field of solid state ionics, developing an extensive patent portfolio, much of which has been licensed to industry.

My guest for this week’s episode is Jacob Glanville. Jacob is the Founder, CEO, and President of Centivax and was formerly the Co-founder, CEO, and President of Distributed Bio. Join us as we sit down with Jake to discuss: how important it is to understand a venture capital firm’s investment thesis and values, tips to successfully pitch to them, the perks of viewing potential VC relationships as “dating,” and how that mindset can help you find the right partner.

Jacob is the Founder, CEO, & President of Centivax and was formerly the Co-founder, CEO, and President of Distributed Bio. Join us as we sit down with Jake, discussing his three-part plan for building Distributed Bio without traditional venture capital, how reality differed from the plan, and how the acquisition by Charles River Laboratories occurred. Learn more about his thoughts on natural team growth and how to handle process drift. Hear Jake’s view on how equipment leasing provided a solution for growing a business when cash was tight and needed for investing in internal operations. Discover Jake’s insight into what he calls “the respiration model” of leadership, balancing hierarchical and organic structures to promote organization and innovation. Hear more about his experience spinning out Centivax.

In part 2 of the Biotech Startups Podcast episode, host Jon Chee dives deeper into his conversation with Jacob Glanville, Founder, CEO, & President of Centivax. Jake sheds light on his past experiences at Rinat Labs, a Pfizer company, and how he found a way to leverage his skills and experience to create new bioinformatic processes. Learn more about his initial idea for a universal vaccine and why he chose to pursue a PhD at Stanford.

In the first ever episode of The Biotech Startups Podcast, Host Jon Chee is joined by Jake Glanville of Centivax! They discuss his upbringing in Guatemala; the parallels between the hospitality service and medicine; how to become more approachable to customers; and the power of saying ‘no’ to people in the industry.

Coming soon... The Biotech Startups Podcast by Excedr. We will be speaking with first-time founders, experienced scientists, long-time company operators, serial entrepreneurs, and biotech investors about the challenges and triumphs of running a biotech startup.